INFY: October 23 puts guidance and trend in focus
INFY Premium research: October 23 puts guidance and trend in focus.
INFY Premium research: October 23 puts guidance and trend in focus.
SFNC Premium research: A cleaner margin meets a costly efficiency test.
MAN Premium research: Recovery meets a demanding cash test.
Oil near $92 and a 10-year yield around 5.35% test a weak sector tape as energy leads premarket and technology research signals stay preliminary.
SMTC Premium research: Growth is visible, duration is the test.
Crude oil jumped about 4% and long Treasury yields climbed before the opening bell, pulling stock futures lower and putting energy inflation back at the center of the premarket.
PTC has a signed all-cash agreement and committed financing, but shareholder approval, regulatory reviews, and a long timetable keep the outcome open.
Vaxcyte’s positive OPUS-1 result reduced clinical uncertainty, while follow-on studies, manufacturing, and review still shape commercial value.
NOVAGOLD has study-stage liquidity and a proposed ownership consolidation, but engineering evidence and future funding remain the defining tests.
WFC Premium research: The earnings test meets a demanding valuation.